Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past

NJ Short, H Kantarjian - The Lancet Haematology, 2023 - thelancet.com
Multidrug chemotherapy has historically been the cornerstone of therapy for both children
and adults with acute lymphocytic leukaemia. However, in the past decade, several novel …
被引用次数：8 相关文章

Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past

NJ Short, H Kantarjian - The Lancet Haematology, 2023 - Elsevier
Multidrug chemotherapy has historically been the cornerstone of therapy for both children
and adults with acute lymphocytic leukaemia. However, in the past decade, several novel …

Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past

NJ Short, H Kantarjian - The Lancet. Haematology, 2023 - pubmed.ncbi.nlm.nih.gov
Multidrug chemotherapy has historically been the cornerstone of therapy for both children
and adults with acute lymphocytic leukaemia. However, in the past decade, several novel …

Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past

NJ Short, H Kantarjian - The Lancet Haematology, 2023 - mdanderson.elsevierpure.com
Multidrug chemotherapy has historically been the cornerstone of therapy for both children
and adults with acute lymphocytic leukaemia. However, in the past decade, several novel …